Aktuelle Aspekte des Pankreaskarzinoms

Klöppel, G.; Sosnowski, Jacek T.; Eichfuss, H. P.; Rückert, K; Klapdor, R

doi:10.1055/s-0028-1129194

Cited by 27 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We ascertained in our prospective study a sensitivity of 92% for this monoganglioside antigen for pancreatic carcinoma, a specificity of 85%, and a total accuracy of 82%. In accordance with the existing findings and the results of Del Villano et al" and Klapdor et al,[1][2][3][4][5][6][7][8][9][10][11][12] who confirmed this high sensitivity, measurement of CA 19-9 value is superior to all other tumor markers in pancreatic carcinoma patients.…”

Section: Discussionsupporting

confidence: 90%

CA 19-9 and pancreatic adenocarcinoma

Safi

Beger

Bittner

et al. 1986

Cancer

View full text Add to dashboard Cite

The diagnostic place value of CA 19-9, a tumor-associated antigen, was tested in 611 patients. This group of patients included 273 patients who suffered from a malignant disease (48 patients with pancreatic carcinomas and 225 patients with extrapancreatic malignant growths) and 338 patients with benign diseases (66 patients with chronic pancreatitis, 36 patients with acute pancreatitis, and 236 patients with general surgical diseases). In 93% of the patients with pancreatic carcinoma (media value, 528 U/ml), in 37% and 19% of the patients with carcinoma of the stomach and colorectal carcinomas (median value 8 U/ml), respectively, the CA 19-9 value was estimated as being above the normal limits of 6 to 37 U/ml. A sensitivity of 93% and a specificity of 85%, as well as a total accuracy of 82%, were established in pancreatic carcinoma during preoperative observation. The preoperatively raised CA 19-9 concentration in patients with pancreatic carcinomas dropped after curative resection of the carcinoma to within normal limits. However, a serum concentration of less than 37 U/ml was not recorded in any CA 19-9 estimation after a palliative surgical intervention, or in any case of inoperable carcinomas.

show abstract

Section: Discussionsupporting

confidence: 90%

CA 19-9 and pancreatic adenocarcinoma

Safi

Beger

Bittner

et al. 1986

Cancer

View full text Add to dashboard Cite

show abstract

“…Our examples of ductal adenocarcinoma, mucinous (colloid) carcinoma, adenosquamous carcinoma and pleomorphic carcinoma of the giant cell type corresponded in frequency age, sex, site, size, spread and prognosis with the relevant data in the literature (Miller et al 1951, Sommers & Meissner 1954, Bell 1957, Frantz 1959, Baylor & Berg 1973, Becker 1973, Kissane 1975, Alguacil-Garcia & Weiland 1977, Tschang et al 1977, Kloppel et al 1979, Cubilla et al 1978, Cubilla & Fitzgerald 1979, Ishikawa et al 1980, Widgren 1980. Prognosis was bad for all these carcinomas, and with no obvious differences between the well-differentiated adenocarcinoma, poorly-differentiated adenocarcinoma and mucinous carcinoma.…”

Section: Exocrine Pancreatic Turnours 657mentioning

confidence: 71%

Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases

1983

Self Cite

View full text Add to dashboard Cite

Based on histopathological examination of 264 exocrine pancreatic tumours (167 autopsy and 97 surgical) from the files of the Institute of Pathology, University of Hamburg, over a 15-yr period (1966-1980), a histogenetic classification is proposed. In addition to the more common neoplasms this also includes rarer and more recently defined entities. Of the 264 tumours, 250 were of duct origin, 10 acinar and four of uncertain histogenesis. Ductal adenocarcinoma, subdivided into a well-differentiated and a poorly-differentiated type, was most frequent (81.1%), followed by its variants: pleomorphic giant cell carcinoma 5.3%, adenosquamous carcinoma 3.8%, and mucinous carcinoma 1.1%. All these had a poor prognosis. Serous cystadenoma (1.1%), mucinous cystic tumour (1.5%) and intraductal papilloma (0.8%), which were rare tumours and mostly apparent in surgical material, proved to be benign or of only latent malignancy. The group of tumours of acinar cell origin consisted of the solid and cystic tumour (2.7%) with favourable prognosis and the acinar cell carcinoma (1.1%). No pancreatoblastoma was observed. The pleomorphic carcinomas of the small cell type (1.5%) were classed as tumours of uncertain histogenesis.

show abstract

“…The TNM classification of the adenocarcinomas of the exocrine pancreas excluding papillary and periampullary carcinomas is of vital importance [9]. One should differentiate particularly all those tumor stages with invasion of neighboring organs; invasion of the duodenum is demonstrated quite often but does not seem to be of decisive prognostic importance.…”

Section: Discussionmentioning

confidence: 99%

Surgical treatment of pancreatic cancer

Kümmerle

Rückert

1984

World j. surg.

Self Cite

View full text Add to dashboard Cite

From 1964 to 1982, there were 782 patients treated for carcinoma of the pancreas. In 174 patients pancreaticoduodenal resection was possible (22%). Until 1977 we performed Whipple procedures, while from 1978 to 1982 total pancreatectomy was preferred. Comparing the results of both methods, we did not find any advantages of total pancreatectomy. Operative mortality did not decrease, survival time did not extend, and the higher resection rates (up to 26%) for more advanced tumor stages were accompanied by greater morbidity. With respect to the patients with inoperable cancer of the pancreas, we found over the last 5 years that the rate of those not undergoing surgery has climbed from 8% to 25%, while the rate of exploratory laparotomies was reduced from 28% to 5%. With the advent of preoperative percutaneous transhepatic cholangio‐drainage (PTCD), the mortality rate of our palliative procedures dropped to 12%. Biliodigestive anastomosis of choice is the hepaticojejunostomy.

show abstract

Aktuelle Aspekte des Pankreaskarzinoms

Cited by 27 publications

References 3 publications

CA 19-9 and pancreatic adenocarcinoma

CA 19-9 and pancreatic adenocarcinoma

Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases

Surgical treatment of pancreatic cancer

Contact Info

Product

Resources

About